Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/08/23
Nektar rallies after releasing new data for rezpeg after Eli Lilly got it wrongProactive Investors • 08/07/23
Nektar Therapeutics' stock jumps premarket after it says data presented by Eli Lilly for a skin treatment was incorrectly calculatedMarket Watch • 08/07/23
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & CompanyPRNewsWire • 08/07/23
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial MarketsPRNewsWire • 08/01/23
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare ConferencePRNewsWire • 06/12/23
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/23
Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 05/02/23
Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical DevelopmentPRNewsWire • 04/27/23
Nektar stock pops as more than half of San Francisco office loses jobs, new CFO appointedMarket Watch • 04/17/23
Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring PlanPRNewsWire • 04/17/23